BioCentury
ARTICLE | Company News

Amoy Diagnostics, Illumina deal

November 2, 2015 8:00 AM UTC

Amoy will develop and commercialize oncology related tests based on Illumina’s next-generation sequencing (NGS) technology, including TruSight Tumor 15, in China. TruSight Tumor 15 is an NGS-based tes...